Overview

Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.

Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
Assess the efficacy and the safety of olesoxime in SMA type 2 or type 3 non ambulant patients aged 3-25 years
Phase:
Phase 2
Details
Lead Sponsor:
Hoffmann-La Roche
Collaborator:
Association Française contre les Myopathies (AFM), Paris